Ascletis Pharma Inc.

Ascletis and Roche Enter Exclusive Pegasys Partnership in China for Viral Hepatitis
2018-11-20
Ascletis Appoints Dr. Lindi Tan as Chief Financial Officer
2018-11-12
Ascletis to Present Phase II / III Clinical Study for Its Innovative All-oral HCV Treatment at the 69th Annual meeting of AASLD
2018-11-06
Ascletis' Ravidasvir NDA Proposed for Priority Review by the CFDA
2018-10-18
Ascletis' Ganovo is Eligible for Shaoxing Government Funding Subsidy Program to Treat HCV Patients
2018-10-15
Ganovo® Enrolled in the Basic Medical Insurance of Tianjin--Capped Reimbursement-Per-Patient Pilot Program
2018-09-26
Ascletis Invited to attend the Summer Davos Forum Tianjin 2018
2018-09-17
Ascletis’ NDA for Its All-oral HCV Treatment Accepted by CFDA
2018-08-01
Ascletis Filed NDA for Its All-oral HCV Treatment
2018-07-31
Ganovo® Phase III Clinical Study Won the Top Award at the Infectious Disease National Congress of Chinese Medical Association
2018-07-30

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1